Home/Filings/4/0000950170-24-097097
4//SEC Filing

LINK WILLIAM J PHD 4

Accession 0000950170-24-097097

CIK 0001819790other

Filed

Aug 13, 8:00 PM ET

Accepted

Aug 14, 4:34 PM ET

Size

12.5 KB

Accession

0000950170-24-097097

Insider Transaction Report

Form 4
Period: 2024-08-12
Transactions
  • Sale

    Common Stock

    2024-08-12$26.53/sh5,021$133,2070 total(indirect: By LLC)
  • Other

    Common Stock

    2024-08-12+10,44610,446 total(indirect: By Link Family Enterprise, LP)
  • Other

    Common Stock

    2024-08-12+27,116167,098 total
  • Other

    Common Stock

    2024-08-1274,89235,000 total(indirect: By LLC)
  • Sale

    Common Stock

    2024-08-12$26.01/sh29,979$779,7545,021 total(indirect: By LLC)
Footnotes (5)
  • [F1]Represents an in-kind pro-rata distribution, and not a purchase or sale, without additional consideration by Flying L Partners XI, LLC to its partners.
  • [F2]The shares are held directly held by Flying L Partners XI, LLC. The Reporting Person is the manager of Flying L Partners XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
  • [F3]The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
  • [F4]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.42 to $26.41. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.42 to $26.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother

Related Parties

1
  • filerCIK 0001228684

Filing Metadata

Form type
4
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 4:34 PM ET
Size
12.5 KB